Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Pei Li Teh and Colin Tan
  • August 23, 2019
  • Webinars

Live webinar from Singapore: Portfolio analysis - Choosing your communication strategy

Live webinar from Singapore: Portfolio analysis - Choosing your communication strategy

Tuesday 1st October 2019 16:00SGT/ 16:00CST/ 17:00JST

Portfolio Analysis and Optimization concentrates on determining the impact that multiple assets have within therapeutic categories, and how the marketing of these assets impacts on overall strategy. This is an important tool for pharmaceutical companies in today’s market. As they simultaneously develop multiple products that can become extremely costly, portfolio management to improve decision-making can have a significant impact on the bottom line. At its very core, it is about selecting how to allocate resources and marketing efforts across multiple assets. 

read more »

  • Posted by Misti Paul and Helen Ansell
  • August 7, 2019
  • Articles

Integrating data

Integrating data

How to conduct an effective epidemiological data review

Clients often ask us if we can triangulate various data sources to fully understand the opportunity for an asset. There are clear benefits - combining primary market research findings with existing data sets provides validity and depth, whilst eliminating many inconsistencies, which helps guide the direction for future marketing strategy and initiatives. 

read more »

How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment

How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment

Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.

read more »

  • Posted by Karen Swords
  • September 25, 2018
  • News

Research Partnership welcomes Misti Paul as Analytics Director

Research Partnership welcomes Misti Paul as Analytics Director

Research Partnership is pleased to welcome Misti Paul, who recently joined the company as Analytics Director.

Misti has over 16 years’ experience in statistical modeling and market research. Before joining Research Partnership, Misti headed up her own advanced statistical consultancy firm Advanced Analytics, providing statistical modeling and consulting services to global pharmaceutical, biotech and medical device companies. She specialised in the areas of merger and acquisition modelling, segmentation, new product development, conjoint methodologies and other analytical techniques.

read more »

  • Posted by Marc Yates
  • September 20, 2018
  • Articles

Comparing apples and oranges: Is a global segmentation transferable?

Comparing apples and oranges: Is a global segmentation transferable?

When our clients are considering primary market research in emerging markets they typically face two challenges - a lack of good local data and budget.

The absence of reliable and up-to-date information in emerging markets should mean that a greater budget is allocated to primary market research. However, in reality the opposite is true. Consequently, our clients want to know if they can tailor global studies to reflect the nuances of different emerging markets.

read more »